UBS Group’s ReShape Lifesciences Inc. Common Stock RSLS Stock Holding History

UBS Group’s Portfolio RSLS Stock Details RSLS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q4	–	Sell	-1,391	Closed	-$9K	–	8572
2018 Q3	$9K	Buy	1,391 +1,379	+11,492%	+$119K	﹤0.01%	7245
2018 Q2	$3K	Buy	12 +11	+1,100%	+$9.4K	﹤0.01%	7689
2018 Q1	$3K	Hold	1	–	–	﹤0.01%	7489
2017 Q4	$2K	Buy	+1	New	+$3.31K	﹤0.01%	7667

Other funds holding RSLS

Sabby Management Miami Beach, Florida $45.1M AUM 74.25% 1-Year Est. Return

UBS Group's RSLS Position: Q4 2018 in Review

UBS Group sold out of ReShape Lifesciences Inc. Common Stock (RSLS) in Q4 2018, closing a stake of 1,391 shares — an estimated $9K sold.

UBS Group first reported a position in RSLS in Q4 2017 and held it in 4 quarters. The position peaked at $9K in Q3 2018. 2 funds tracked by Wall St. Rank hold RSLS as of Q4 2018.

UBS Group reported no remaining ReShape Lifesciences Inc. Common Stock position as of Q4 2018 after selling out during the quarter.
UBS Group sold 1,391 ReShape Lifesciences Inc. Common Stock shares in Q4 2018, an estimated $9K.
UBS Group first reported a position in ReShape Lifesciences Inc. Common Stock in Q4 2017 and held it in 4 quarters.
UBS Group's ReShape Lifesciences Inc. Common Stock position peaked at $9K in Q3 2018.
2 funds tracked by Wall St. Rank held ReShape Lifesciences Inc. Common Stock as of Q4 2018.

Based on UBS Group's 13F filing for Q4 2018, filed 14 Feb 2019.